CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment

Pharmacogenetics and Genomics

Volumn 23, Issue 11, 2013, Pages 627-630

  Almoguera, Berta ^a,c   Riveiro Alvarez, Rosa ^a,c   Lopez Castroman, Jorge ^b,c   Dorado, Pedro ^c,h   Vaquero Lorenzo, Concepción ^d   Fernandez Piqueras, José ^c,d   Llerena, Adrián ^c,h   Abad Santos, Francisco ^e,f   Baca García, Enrique ^b,c,i   Dal Ré, Rafael ^g   Ayuso, Carmen ^a,c  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^b 28400 Madrid   (Japan)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g UNIVERSIDAD REY JUAN CARLOS   (Spain)

^h UNIVERSITY OF EXTREMADURA   (Spain)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

CYP2D6; Effectiveness; MDR1; Pharmacogenetics; Risperidone; Schizophrenia

Indexed keywords

CYTOCHROME P450 2D6; RISPERIDONE;

ADULT; ARTICLE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CYTOCHROME P-450 CYP2D6; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA;

EID: 84886597555     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283659a94     Document Type: Article

References (8)

1. Llerena A, Berecz R, Peñas-Lledó E, Sü veges A, Fariñas H. Pharmacogenetics of clinical response to risperidone. Pharmacogenomics 2013; 14: 177-194.
2. Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Vaquero-Lorenzo C, Fernandez-Piqueras J, et al. Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. Pharmacogenomics J 2013; 13: 197-204.
3. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
4. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 2009; 438: 7-14.
5. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234-242.
6. De Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15-27.
7. Mas S, Gasso P, Alvarez S, Parellada E, Bernardo M, Lafuente A. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J 2012; 12: 255-259.
8. Bartecek R, Jurica J, Zrustova J, Kasparek T, Pindurova E, Zourkova A. Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. Neuro Endocrinol Lett 2012; 33: 236-244.